275 related articles for article (PubMed ID: 31779986)
1. Will new agents impact survival in AML?
Rowe JM
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101094. PubMed ID: 31779986
[TBL] [Abstract][Full Text] [Related]
2. New drugs creating new challenges in acute myeloid leukemia.
Tiong IS; Wei AH
Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
[TBL] [Abstract][Full Text] [Related]
3. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
Stone RM
Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
[TBL] [Abstract][Full Text] [Related]
4. Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Estey E; Karp JE; Emadi A; Othus M; Gale RP
Leukemia; 2020 Mar; 34(3):671-681. PubMed ID: 31915366
[TBL] [Abstract][Full Text] [Related]
5. What to use to treat AML: the role of emerging therapies.
Thol F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
[TBL] [Abstract][Full Text] [Related]
6. How I treat acute myeloid leukemia in the era of new drugs.
DiNardo CD; Wei AH
Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470
[TBL] [Abstract][Full Text] [Related]
7. 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
Tang K; Schuh AC; Yee KW
Curr Oncol Rep; 2021 Aug; 23(10):120. PubMed ID: 34350512
[TBL] [Abstract][Full Text] [Related]
8. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
Talati C; Sweet K
Leuk Res; 2018 Oct; 73():58-66. PubMed ID: 30223250
[TBL] [Abstract][Full Text] [Related]
9. The growing landscape of FLT3 inhibition in AML.
Smith CC
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):539-547. PubMed ID: 31808872
[TBL] [Abstract][Full Text] [Related]
10. The Time Has Come for Targeted Therapies for AML: Lights and Shadows.
Fiorentini A; Capelli D; Saraceni F; Menotti D; Poloni A; Olivieri A
Oncol Ther; 2020 Jun; 8(1):13-32. PubMed ID: 32700072
[TBL] [Abstract][Full Text] [Related]
11. AML: New Drugs but New Challenges.
Burnett A; Stone R
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):341-350. PubMed ID: 32151586
[TBL] [Abstract][Full Text] [Related]
12. Incorporating newer agents in the treatment of acute myeloid leukemia.
Raj RV; Abedin SM; Atallah E
Leuk Res; 2018 Nov; 74():113-120. PubMed ID: 30401522
[TBL] [Abstract][Full Text] [Related]
13. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Wei AH; Tiong IS
Blood; 2017 Dec; 130(23):2469-2474. PubMed ID: 29051180
[TBL] [Abstract][Full Text] [Related]
14. New drugs approved for acute myeloid leukaemia in 2018.
Kucukyurt S; Eskazan AE
Br J Clin Pharmacol; 2019 Dec; 85(12):2689-2693. PubMed ID: 31469910
[TBL] [Abstract][Full Text] [Related]
15. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
16. Progress and predictions: AML in 2018.
Rowe JM
Best Pract Res Clin Haematol; 2018 Dec; 31(4):337-340. PubMed ID: 30466743
[TBL] [Abstract][Full Text] [Related]
17. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.
Megías-Vericat JE; Solana-Altabella A; Ballesta-López O; Martínez-Cuadrón D; Montesinos P
Ann Hematol; 2020 Sep; 99(9):1989-2007. PubMed ID: 32683457
[TBL] [Abstract][Full Text] [Related]
18. [Novel Strategies to Treat Acute Myeloid Leukemia].
Gediga MHE; Middeke JM; Ruhnke L
Dtsch Med Wochenschr; 2023 Apr; 148(8):451-458. PubMed ID: 36990117
[TBL] [Abstract][Full Text] [Related]
19. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
20. Single-agent and combination biologics in acute myeloid leukemia.
Richard-Carpentier G; DiNardo CD
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):548-556. PubMed ID: 31808888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
